Summary:
A phase 1/2/3 Randomized Study to evaluate the safety tolerability and immunogenicity of a modified RNV vaccine against influenza in healthy individuals.
Qualified Participants May Receive:
Qualified participants will receive $400.00 for every completed study visit.